NICE to allow innovative new medicines to be used in the NHS.
The BioIndustry Association welcomes today’s announcement by the National Institute for Health and Clinical Excellence (NICE) to conduct a consultation on the introduction of an Innovation Pass.
The Innovation Pass was proposed in the OLS’s “Life Sciences Blueprint”, which was published in July.
The BIA played a pivotal role in the delivery of the Blueprint by Lord Drayson and the OLS.
Clive Dix, BIA Chairman, said:
“The introduction of an Innovation Pass will allow patients with unmet medical needs to gain early access to the innovative technologies being developed by life sciences companies.
It also signals to the investment community that the government understand and supports the innovative life science sector in the UK.
“The BIA has been working closely with the OLS and other life sciences trade associations to bring about the successful introduction of the Innovation Pass as part of a package of measures designed to ensure the future sustainability of the UK life sciences sector.”